The 2-hydroxy-nevirapine metabolite as a candidate for boosting apolipoprotein A1 and for modulating anti-HDL antibodies-Reference-Cited by-同舟云学术

The 2-hydroxy-nevirapine metabolite as a candidate for boosting apolipoprotein A1 and for modulating anti-HDL antibodies

Published:2021-03 Issue: Volume:165 Page:105446
ISSN:1043-6618
Container-title:Pharmacological Research
language:en
Short-container-title:Pharmacological Research

Author:

Marinho Aline T.^ORCID,Batuca Joana R.,Miranda Joana P.,Caixas Umbelina,Dias Clara G.,Branco Teresa,Soto Karina^ORCID,Pinheiro Pedro^ORCID,Bourbon Mafalda,Marques M. Matilde,Antunes Alexandra M.,Monteiro Emília C.,Pereira Sofia A.^ORCID

Funder

European Regional Development Fund

Ministério da Educação e Ciência

Fundação para a Ciência e a Tecnologia

Instituto Nacional de Ciência e Tecnologia para Excitotoxicidade e Neuroproteção

Publisher

Elsevier BV

Subject

Pharmacology

Reference58 articles.

1. Present therapeutic role of cholesteryl ester transfer protein inhibitors;Ferri;Pharmacol. Res.,2018

2. Molecular mechanisms responsible for the antiinflammatory and protective effect of HDL on the endothelium;Norata;VHRM,2005

3. Anti-oxidant properties of high-density lipoprotein and atherosclerosis: HDL: composition and anti-oxidant activity;Podrez;Clin. Exp. Pharmacol. Physiol.,2010

4. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids;Navab;J. Lipid Res.,2001

5. Extended‐release niacin increases anti‐apolipoprotein A‐I antibodies that block the antioxidant effect of high‐density lipoprotein–cholesterol: the EXPLORE clinical trial;Batuca;Br. J. Clin. Pharmacol.,2017

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HDL-based therapeutics: A promising frontier in combating viral and bacterial infections;Pharmacology & Therapeutics;2024-08

2. People living with HIV display increased anti-apolipoprotein A1 auto-antibodies, inflammation, and kynurenine metabolites: a case–control study;Frontiers in Cardiovascular Medicine;2024-02-13